Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: December 4, 2023
Company: Oragenics, Inc.
Event: Amendment to Articles of Incorporation to designate Series F Convertible Preferred Stock in anticipation of an asset purchase from Odyssey Health, Inc.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data points relate to the proposed transaction:
- Transaction Consideration: $1,000,000 in cash and 8,000,000 shares of Series F Convertible Preferred Stock.
- Authorized Preferred Stock: 50,000,000 shares total; 9,871,728 shares currently designated, issued, and outstanding.
- Proposed Common Stock Increase: Request to increase authorized common stock from 4,166,666 to 350,000,000 shares.
Material Changes
The filing reports the following material changes and actions:
- Asset Purchase Agreement: Oragenics agreed to purchase assets related to medical products for brain-related illnesses from Odyssey Health, Inc.
- Stock Designation: The Board authorized and filed a Certificate of Designation for 8,000,000 shares of Series F Convertible Preferred Stock.
- Capital Structure Impact: The transaction requires a significant increase in authorized common stock to accommodate the conversion of the Series F shares.
Outlook, Risks, and Contingencies
Transaction Conditions: The issuance of common stock upon conversion of Series F Preferred Stock is contingent upon:
- Shareholder approval of the stock issuance and the increase in authorized common stock.
- Compliance with NYSE American rules.
- Closing of the Odyssey Asset Purchase.
Conversion Restrictions: Even with shareholder approval, Odyssey cannot convert Series F shares into more than 19.9% of the Company's common stock outstanding until:
- The Company is approved for initial listing on the NYSE American or another national exchange, or is delisted from NYSE American.
- Shareholders approve any change of control deemed to occur upon conversion.
Shareholder Meeting: The Company anticipates presenting these matters to shareholders at its annual meeting on December 14, 2023.
Investor Verification Checklist
- Verify the outcome of the shareholder vote scheduled for December 14, 2023, regarding the increase in authorized common stock and the issuance of shares upon conversion.
- Confirm the closing status of the Odyssey Asset Purchase Agreement.
- Monitor the Company's listing status on the NYSE American, as conversion limits are tied to exchange listing rules.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for detailed terms of the Series F Preferred Stock.